Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06028074 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
A Phase 1 study of Advanced Solid Malignancies, sponsored by Georgiamune.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 111
- Enrollment target
- 11
- Study locations
NCT06028074 is a Phase 1 study of Advanced Solid Malignancies that is actively recruiting participants, run by Georgiamune. The registered enrollment target is 111 participants, below the 227-participant average among 6 other Advanced Solid Malignancies trials with a reported enrollment target (51% lower). The trial reports 11 study locations across 7 states.
The verdict
NCT06028074, a Phase 1 study of Advanced Solid Malignancies, is actively recruiting participants, sponsored by Georgiamune.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 111 participants
- Enrollment target
- 11
- Study locations
Study Summary
GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.
Conditions Studied
Interventions
- DRUG GIM122
Study Locations (11)
California
- The Angeles Clinic and Research Institute - Los Angeles
- USC/Norris Comprehensive Cancer Center - Los Angeles
- UCLA Hematology/Oncology - Los Angeles
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Texas
- Texas Oncology - Baylor Sammons Cancer Center - Dallas
- NEXT Oncology Dallas - Irving
Florida
- Florida Cancer Specialists - Sarasota
Kentucky
- Norton Cancer Institute - Louisville
New Jersey
- Rutgers Cancer Institute of NJ - New Brunswick
Tennessee
- Tennessee Oncology, PLLC - Nashville
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2023-12-12 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06028074
The ClinicalTrials.gov registry entry for NCT06028074 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 227-participant average among 6 other Advanced Solid Malignancies trials with a reported enrollment target (51% lower). The listed sponsor is Georgiamune, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Malignancies appearing as the primary indexed condition, and to 1 intervention - of which GIM122 is the first listed.
NCT06028074 reports 11 study locations spanning 7 distinct geographic areas - top geographies include California, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT06028074 about?
NCT06028074 is a clinical study titled "Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies". GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.
What is the current status of trial NCT06028074?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 111 participants. The study started on 2023-12-12. Estimated completion is 2026-12.
What conditions does trial NCT06028074 study?
This clinical trial studies the following conditions: Advanced Solid Malignancies.
What interventions are being tested in trial NCT06028074?
The interventions under investigation include: GIM122 (DRUG).
Who is sponsoring clinical trial NCT06028074?
This trial is sponsored by Georgiamune, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06028074 being conducted?
This trial has 11 study locations across California, Florida, Kentucky, New Jersey, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)
ACTIVE NOT RECRUITING · Phase 1
-
Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.